Abstract

Study Design: Prospective, interventional, non-comparative study
Purpose: To evaluate the efficacy and safety profile of 0.5% Timolol gel in the treatment of periocular pyogenic granulomas(PG).
Methods: 20 cases of conjunctival PGs were prescribed topical timolol gel twice a day and followed up over a period of 3 months. The maximum dimensions of the lesion, colour (for vascularity), the number of bleeding episodes, and the adverse effect profile, including tests for tear film stability were noted.
Results: We found a significant reduction in the sizeof the lesions(P=0.026), colour scale(p<0.01) and the number of bleeding episodes(p<0.01). There was no significant change in the pulse, blood pressure, visual acuity or intraocular pressure, but a significant decrease in the tear film breakup time. Minor adverse events included dry eye(15%) and papillae(15%).
Conclusion: Timolol gel is a safe and effective option for the treatment of periocular PGs, with no serious adverse effects.